TipRanks
Go Ultimate55% OFF
PC:ERADI

Eradivir Inc: Valuation, Funding & Investors

Eradivir Inc. is a privately held, clinical-stage biotechnology company dedicated to leveraging the immune system to target and treat viral infections and other diseases. Utilizing its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform, Eradivir combines the simplicity of small molecule therapies with the efficacy of antibody therapies to enable rapid and selective destruction of diseased cells. The company's lead antiviral therapeutic, EV25, is in Phase 2 trials for influenza, while EV148 is being developed for respiratory syncytial virus (RSV).

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$10M
Total Funding Rounds
1
Latest Funding Amount
$10M
Latest Funding Round
Investment

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Oct 08, 2025Investment$10.00M―

Similar Companies

A snapshot of private companies similar to Eradivir Inc, helping you discover and navigate related company profiles.

Related News and Analysis